Isolated systolic hypertension of young-to-middle-age individuals implies a relatively low risk of developing hypertension needing treatment when central blood pressure is low

2011 ◽  
pp. 1 ◽  
Author(s):  
Francesca Saladini ◽  
Massimo Santonastaso ◽  
Lucio Mos ◽  
Elisabetta Benetti ◽  
Nello Zanatta ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Middle Age ◽  
Low Risk ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension

ISOLATED SYSTOLIC HYPERTENSION OF THE YOUNG IS AT LOW RISK WHEN CENTRAL BLOOD PRESSURE IS LOW: PP.10.399

2010 ◽  
Vol 28 ◽  
pp. e169-e170
Author(s):  
F Saladini ◽  
F Ragazzo ◽  
M Santonastaso ◽  
A Mazzer ◽  
P Bratti ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Low Risk ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension

scholarly journals Isolated systolic hypertension and central blood pressure: Implications from the national nutrition and health survey in Taiwan

2020 ◽  
Author(s):  
Shao‐Yuan Chuang ◽  
Hsing‐Yi Chang ◽  
Tsung‐Ying Tsai ◽  
Hao‐Min Cheng ◽  
Wen‐Harn Pan ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Health Survey ◽  
Systolic Hypertension ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension ◽  
Nutrition And Health

scholarly journals P.15 Isolated Systolic Hypertension and Central Blood Pressure: Implications from the National Nutrition and Health Survey in Taiwan

2020 ◽  
Vol 26 (Supplement 1) ◽  
pp. S36
Author(s):  
Shao-Yuan Chuang ◽  
Hsing-Yi Chang ◽  
Hao-Min Cheng ◽  
Wen-Harn Pan ◽  
Chen-Huan Chen
Keyword(s):  
Blood Pressure ◽  
Health Survey ◽  
Systolic Hypertension ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension ◽  
Nutrition And Health

Central blood pressure and pulse wave velocity in young and middle-aged Japanese adults with isolated systolic hypertension

2019 ◽  
Vol 43 (3) ◽  
pp. 207-212 ◽  
Author(s):  
Atsushi Nakagomi ◽  
Fumio Imazeki ◽  
Motoi Nishimura ◽  
Yuji Sawabe ◽  
Kazuyuki Matsushita ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Systolic Hypertension ◽  
Pulse Wave ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension ◽  
Middle Aged ◽  
Japanese Adults

scholarly journals Comparison of the Effects of Antihypertensive Agents on Central Blood Pressure and Arterial Stiffness in Isolated Systolic Hypertension

Hypertension ◽  
2009 ◽  
Vol 54 (2) ◽  
pp. 409-413 ◽  
Author(s):  
Isla S. Mackenzie ◽  
Carmel M. McEniery ◽  
Zahid Dhakam ◽  
Morris J. Brown ◽  
John R. Cockcroft ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Arterial Stiffness ◽  
Systolic Hypertension ◽  
Antihypertensive Agents ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension

scholarly journals Predictors of high central blood pressure in young with isolated systolic hypertension

2016 ◽  
Vol Volume 12 ◽  
pp. 321-328 ◽  
Author(s):  
Ganna Radchenko ◽  
Olena Torbas ◽  
Yuriy Sirenko
Keyword(s):  
Blood Pressure ◽  
Systolic Hypertension ◽  
Central Blood Pressure ◽  
Isolated Systolic Hypertension

scholarly journals Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial

2001 ◽  
Vol 2 (1_suppl) ◽  
pp. S217-S222
Author(s):  
Matthew R Weir ◽  
Rebecca Y Wang
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Systolic Hypertension ◽  
Large Scale ◽  
Candesartan Cilexetil ◽  
Antihypertensive Drugs ◽  
Isolated Systolic Hypertension ◽  
Open Label ◽  
Background Therapy ◽  
Receptor Blockers

Angiotensin II (Ang II) receptor blockers are the newest class of antihypertensive drugs to be developed. No large-scale clinical trials have been performed to evaluate their efficacy alone, or in combination with other drugs. A large-scale, eight week, open-label, non-placebo-controlled, single-arm trial evaluated the efficacy, tolerability and dose-response of candesartan cilexetil, 16—32 mg once-daily, either as monotherapy or as part of combination therapy, in a diverse hypertensive population in actual practice settings. 6465 patients with high blood pressure, of whom 52% were female and 16% African American, with a mean age of 58 years, were included. 5446 patients had essential hypertension and 1014 patients had isolated systolic hypertension. In order to be included in this study, patients had either untreated or uncontrolled hypertension (systolic blood pressure (SBP) 140—179 mmHg and/or diastolic blood pressure (DBP) 90—109 mmHg inclusive at baseline), despite a variety of other antihypertensive drugs. Of the 5156 patients with essential hypertension and at least one post baseline efficacy measurement, the mean pretreatment blood pressure (BP) was 156/97 mmHg. Candesartan cilexetil monotherapy reduced mean SBP/DBP by 18.0/12.2 mmHg. Similarly, in the 964 patients with isolated systolic hypertension and at least one post baseline efficacy measurement, candesartan cilexetil monotherapy reduced SBP/DBP from 158/81 by 16.5/4.5 mmHg. Candesartan cilexetil was similarly effective when employed as add-on therapy. When added to baseline antihypertensive medication in 51% of the patients with essential hypertension not achieving BP control, additional reduction in BP was achieved regardless of the background therapy, including diuretics (17.8/11.7 mmHg) calcium antagonists (16.6/11.2 mmHg), beta-blockers (16.5/10.4 mmHg), angiotensin-converting enzyme inhibitors (ACE-I) (15.3/10.0 mmHg), and alpha blockers (16.4/10.4 mmHg). Likewise, when candesartan cilexetil was used as add-on therapy in patients with isolated systolic hypertension, there was a consistent further reduction of mean SBP/DBP, regardless of the background therapy. Moreover, these monotherapeutic or add-on efficacy benefits were seen regardless of age (<65 or >65 years), gender, or race. Despite the open-label design of the study which enhances efficacy owing to the placebo effect, the Ang II receptor blocker, candesartan cilexetil either alone, or as an add-on therapy, is highly effective for assisting in the control of systolic and diastolic hypertension.

Arterial hypertension + past stroke – a case report

2021 ◽  
Vol 14 (3) ◽  
pp. 324-326
Author(s):  
Maria Łukasiewicz ◽  
Marta Swarowska-Skuza
Keyword(s):  
Blood Pressure ◽  
Case Report ◽  
Chronic Disease ◽  
Side Effects ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Systolic Hypertension ◽  
The Elderly ◽  
Isolated Systolic Hypertension ◽  
Special Group

Arterial hypertension, as a very widespread chronic disease, and thus differing in both pathomechanism and course in patients, requires a significant individualization of pharmacotherapy. One such special group is the elderly. Both the low-renin pathomechanism of arterial hypertension and its phenotype (isolated systolic hypertension) imply the choice of a specific pharmacotherapy. Additionally, in this group, side effects should be observed much more vigilantly, while target blood pressure values should be treated more liberally. An example of antihypertensive therapy in a patient belonging to the group described is presented in the following case.

Sign in / Sign up

Export Citation Format

Share Document